ArticleThe American journal of case reports2020

Durable Response to Brentuximab Vedotin-Based Chemotherapy in Refractory Hodgkin Lymphoma with Central Nervous System (CNS) Involvement.

Heidi Mociková et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.